(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 July 2009 (23.07.2009)

PCT

(10) International Publication Number
WO 2009/090414 A1

(51) International Patent Classification:
C07D 401/06 (2006.01) *A61P 29/00* (2006.01)
A61K 31/4439 (2006.01)

(21) International Application Number:
PCT/GB2009/000142

(22) International Filing Date: 19 January 2009 (19.01.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0800874.0 18 January 2008 (18.01.2008) GB
0820526.2 10 November 2008 (10.11.2008) GB

(71) Applicant *(for all designated States except US)*: **OXAGEN LIMITED** [GB/GB]; 91 Milton Park, Abingdon, Oxon OX14 4RY (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ARMER, Richard, Edward** [GB/GB]; Oxagen Limited, 91 Milton Park, Abingdon, Oxon OX14 4RY (GB). **PETTIPHER, Eric, Roy** [GB/GB]; Oxagen Limited, 91 Milton Park, Abingdon, Oxon OX14 4RY (GB). **WHITTAKER, Mark** [GB/GB]; Oxagen Limited, 91 Milton Park, Abingdon, Oxon OX14 4RY (GB). **WYNNE, Graham, Michael** [GB/GB]; Summit Corporation Plc, 91 Milton Park, Abingdon, Oxon OX14 4RY (GB). **VILE, Julia** [GB/GB]; Summit Corporation Plc, 91 Milton Park, Abingdon, Oxon OX14 4RY (GB). **SCHROER, Frank** [NL/GB]; Summit Corporation Plc, 91 Milton Park, Abingdon, Oxon OX14 4RY (GB).


(74) Agent: **ROBERTS, Alison, Christine**; Kilburn & Strode LLP, 20 Red Lion Street, London WC1R 4PJ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(54) Title: COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY



(I)

(57) Abstract: Compounds of general formula (I) wherein W is chloro or fluoro; R^1 is phenyl optionally substituted with one or more substituents selected from halo, -CN, -C_1-C_6 alkyl, -SOR^3, -SO_2R^3, -$SO_2N(R^2)_2$, -$N(R^2)_2$, -$NR^2C(O)R^3$, -CO_2R^2, -$CONR^2R^3$, -NO_2, -OR^2, -SR^2, -$O(CH_2)_pOR^2$, and -$O(CH_2)_pO(CH_2)_qOR^2$ wherein each R^2 is independently hydrogen, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, aryl or heteroaryl; each R^3 is independently, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

WO 2009/090414 A1